On Wednesday February 28, 2024, Lyell Immunopharma Reported Q4 Adjusted. EPS $(0.17) Beats $(0.23) Estimate, Sales $13.00K Down From $48.39M YoY
On Wednesday February 28, 2024, Lyell Immunopharma Reported Q4 Adjusted. EPS $(0.17) Beats $(0.23) Estimate, Sales $13.00K Down From $48.39M YoY
2024年2月28日星期三，Lyell Immunopharma公布了经调整后的第四季度业绩。每股收益（0.17）超过预期（0.23）美元，销售额低于同比4,839万美元
Lyell Immunopharma (NASDAQ:LYEL) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.23) by 26.09 percent. The company reported $13.00 thousand in sales this quarter. This is a 99.97 percent decrease over sales of $48.39 million the same period last year.
莱尔免疫制药（纳斯达克股票代码：LYEL）公布的季度亏损为每股0.17美元（0.17美元），比分析师共识估计的美元（0.23美元）高出26.09％。该公司报告本季度销售额为13,000美元。这比去年同期的4,839万美元销售额下降了99.97％。